MAPT and Alzheimer disease: Donanemab, a monoclonal antibody targeting the N-terminal pyroglutamate Aβ epitope, was first evaluated in the Phase 2 TRAILBLAZER-ALZ trial (NCT03367403), which enrolled 272 patients with early symptomatic or mild AD and confirmed amyloid and tau pathology.